Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) have transformed medical weight loss. Patients are achieving remarkable, sustained fat reduction. However, a significant weight loss journey often reveals two aesthetic challenges: stubborn fat pockets  that resist the medication, and the crucial need to maintain muscle tone  and skin firmness . This leads to the question we hear most often from our successful patients: When is the right time to transition f

The weight loss results achieved with GLP-1 receptor agonists—such as Semaglutide and Tirzepatide —are transformative. Patients experience significant, life-changing reductions in body weight and visceral fat. However, even after reaching your goal weight, one common challenge remains: stubborn, localized fat pockets  that resist diet and exercise. These areas (like the lower abdomen, flanks, or thighs) are genetically determined and often don't disappear completely. This is